Literature DB >> 27899201

Revisiting Milan cervical cancer study: Do the original findings hold in the era of chemotherapy?

W Ross Green1, Lara Hathout1, Atif J Khan1, Mohamed A Elshaikh2, Sushil Beriwal3, William Small4, Omar Mahmoud5.   

Abstract

BACKGROUND: The primary treatment of early stage cervical carcinoma (IB-IIA) is either surgery or radiation therapy based on the pivotal Milan randomized study published twenty years ago. In the presence of high-risk features, the gold standard treatment is concurrent chemotherapy and radiation therapy (CRT) whether it is the in the postoperative or the definitive setting. Using the National Cancer Data Base (NCDB), the goal of our study is to compare the outcomes of surgery and radiation therapy in the chemotherapy era.
METHODS: Between 2004 and 2013, 5478 patients diagnosed with early stage cervical cancer were divided into 2 groups based on their primary treatment: non-surgical (n=1980) and surgical groups (n=3498). The distribution of patient/tumor characteristics and treatment variables with their relation to overall survival and proportional regression models were assessed to investigate the superiority of one approach over the other. Propensity score analysis adjusted for imbalance of covariates to create a well-matched-patient cohort.
FINDINGS: At 46months median follow-up, the 5-year overall survival was similar between both groups (73·8% vs. 75.7%; p=0.619) after applying propensity score analysis. On multivariate analysis, high Charlson comorbidity score, stage IIA disease, larger tumor size, positive lymph nodes and high-grade disease were significant predictors of poor outcome while older age and treatment approach were not.
INTERPRETATION: Our analysis suggests that surgery (followed by adjuvant RT or CRT) and definitive radiotherapy (with or without chemotherapy) result in equivalent survival. Prospective studies are warranted to establish this paradigm in the chemotherapy era.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjuvant chemoradiotherapy; Definitive chemoradiotherapy; Early stage cervical cancer

Mesh:

Year:  2016        PMID: 27899201     DOI: 10.1016/j.ygyno.2016.11.034

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group.

Authors:  Shogo Shigeta; Muneaki Shimada; Keita Tsuji; Tomoyuki Nagai; Yasuhito Tanase; Koji Matsuo; Shoji Kamiura; Takashi Iwata; Harushige Yokota; Mikio Mikami
Journal:  Int J Clin Oncol       Date:  2022-06-14       Impact factor: 3.850

2.  Long noncoding RNA ZNF667-AS1 reduces tumor invasion and metastasis in cervical cancer by counteracting microRNA-93-3p-dependent PEG3 downregulation.

Authors:  Yong-Jie Li; Zhe Yang; Yi-Ying Wang; Yue Wang
Journal:  Mol Oncol       Date:  2019-10-17       Impact factor: 6.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.